Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MSD India

Division of Merck & Co. Inc.
www.msdindia.in

Latest From MSD India

Will Keytruda Price Differential Really Count In India?

Merck has launched Keytruda at an “India-specific” price but some experts say that the immuno-oncology therapy will likely still be beyond the reach of a majority of patients. Merck though also expects to offer a patient access program for those who can’t afford the therapy.

Commercial Strategy

Indian Teneligliptin Saga: Brands Bazaar, Surging Volumes

More than two dozen brands, a sharp spurt in sales volumes and a price decline of over 60% currently appear to characterize the market for the type 2 diabetes therapy teneligliptin in India. And market watchers claim that teneligliptin volumes in the country have surpassed the combined numbers of some of the more established gliptins, including vildagliptin and sitagliptin.

Commercial Market Intelligence

Korean Gliptins Loom Amid Signs Of Shifts In India

A clutch of new dipeptidyl peptidase-4 (DPP-4) inhibitors including LG Life Sciences Ltd's gemigliptin and Dong-A ST Co. Ltd 's evogliptin have either just hit the Indian market or are on the horizon amid what some industry watchers say are early signs of a shake-up in volumes in the highly competitive domestic gliptins market.

Companies India

Merck Wards Off More Januvia Infringers In India

Merck & Co has moved to fend off a clutch of smaller Indian players that allegedly contract manufacture and export two of its diabetes therapies, or hope to introduce copies of these on the domestic market, infringing on its patents.

BioPharmaceutical India
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • India
  • Parent & Subsidiaries
  • Merck & Co. Inc.
  • Senior Management
  • KG Ananthakrishnan, Managing Dir.
    Giri Giridhar, Sr. Dir., Fin.
    Swashraya Shah, MD, Sr. Dir., Med. Affairs
    Neelima Dwivedi, Sr. Dir., Corp. Affairs
  • Contact Info
  • MSD India
    Phone: 22 67898888
    Platina 8th Fl. C. 59, G Block
    Bandra Kurla
    Mumbai, 400098
    India
Advertisement
Advertisement
UsernamePublicRestriction

Register